Alkermes plc (NASDAQ:ALKS) Receives $44.07 Consensus Target Price from Brokerages

Alkermes plc (NASDAQ:ALKS) has received a consensus rating of “Moderate Buy” from the eighteen analysts that are presently covering the company, Marketbeat reports. Five analysts have rated the stock with a hold recommendation, twelve have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $44.0667.

ALKS has been the subject of several research reports. Wolfe Research initiated coverage on shares of Alkermes in a research report on Monday, February 23rd. They issued an “outperform” rating and a $45.00 price target for the company. Royal Bank Of Canada lowered their price objective on shares of Alkermes from $47.00 to $45.00 and set an “outperform” rating on the stock in a report on Thursday, February 26th. Wells Fargo & Company lifted their price objective on shares of Alkermes from $37.00 to $43.00 and gave the company an “overweight” rating in a report on Thursday, February 26th. Bank of America boosted their target price on shares of Alkermes from $33.00 to $34.00 and gave the stock a “neutral” rating in a research report on Friday, February 20th. Finally, Wall Street Zen lowered shares of Alkermes from a “buy” rating to a “hold” rating in a report on Saturday, February 28th.

Insider Buying and Selling

In other news, SVP Christian Todd Nichols sold 6,000 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $30.00, for a total value of $180,000.00. Following the transaction, the senior vice president owned 109,769 shares in the company, valued at $3,293,070. This trade represents a 5.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Craig C. Hopkinson sold 9,000 shares of Alkermes stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $29.72, for a total value of $267,480.00. Following the transaction, the executive vice president directly owned 89,389 shares in the company, valued at approximately $2,656,641.08. The trade was a 9.15% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 157,434 shares of company stock valued at $5,305,794. Company insiders own 4.40% of the company’s stock.

Institutional Investors Weigh In On Alkermes

A number of institutional investors and hedge funds have recently bought and sold shares of ALKS. Assetmark Inc. boosted its holdings in Alkermes by 933.8% during the 3rd quarter. Assetmark Inc. now owns 827 shares of the company’s stock worth $25,000 after acquiring an additional 747 shares during the last quarter. Cullen Frost Bankers Inc. bought a new stake in shares of Alkermes in the 4th quarter worth $28,000. Johnson Financial Group Inc. purchased a new stake in shares of Alkermes in the third quarter valued at about $31,000. UMB Bank n.a. lifted its position in shares of Alkermes by 57.6% during the fourth quarter. UMB Bank n.a. now owns 1,220 shares of the company’s stock valued at $34,000 after purchasing an additional 446 shares in the last quarter. Finally, Salomon & Ludwin LLC lifted its position in shares of Alkermes by 115.6% during the fourth quarter. Salomon & Ludwin LLC now owns 1,244 shares of the company’s stock valued at $35,000 after purchasing an additional 667 shares in the last quarter. 95.21% of the stock is owned by hedge funds and other institutional investors.

Alkermes Trading Up 1.1%

ALKS stock traded up $0.31 during trading on Friday, reaching $27.95. 200,054 shares of the stock were exchanged, compared to its average volume of 2,050,651. The firm’s 50 day moving average is $31.59 and its 200 day moving average is $30.19. The firm has a market cap of $4.66 billion, a P/E ratio of 19.56, a price-to-earnings-growth ratio of 6.93 and a beta of 0.53. Alkermes has a twelve month low of $25.17 and a twelve month high of $36.32.

Alkermes (NASDAQ:ALKS) last announced its quarterly earnings data on Wednesday, February 25th. The company reported $0.29 EPS for the quarter, missing analysts’ consensus estimates of $0.43 by ($0.14). Alkermes had a net margin of 16.37% and a return on equity of 14.91%. The firm had revenue of $384.55 million during the quarter, compared to analyst estimates of $380.44 million. During the same period last year, the business posted $1.05 EPS. The company’s revenue was down 10.6% on a year-over-year basis. Alkermes has set its FY 2026 guidance at -0.798–0.680 EPS. As a group, analysts predict that Alkermes will post 1.31 earnings per share for the current fiscal year.

About Alkermes

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.